Bharucha David 4/A

What Happened
David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals (MIST), was granted a derivative award covering 204,000 shares on February 2, 2026. The filing shows the acquisition price as $0.00 and is an amended Form 4 correcting prior exercise-price information. This was a grant (not an open-market purchase or sale) and the shares are subject to vesting.

Key Details

• Transaction date: February 2, 2026 (reported on amended Form 4 filed Feb 5, 2026).
• Transaction type: Derivative award/grant for 204,000 shares; reported price $0.00.
• Shares owned after transaction: Not specified in this filing.
• Footnotes:
  • F1: The exercise price on the initial filings was incorrectly stated (this filing amends that).
  • F2: Vesting schedule — 1/4 of the option vests on Feb 2, 2027, then 1/36th of the remaining shares vests each month thereafter, contingent on continued service.
• Filing status: Amended Form 4 (correction to earlier filing).

Context
This is a derivative grant subject to time-based vesting; it does not represent an immediate sale or open-market purchase. For retail investors, such grants are common for employee compensation and do not by themselves indicate buying or selling conviction. The amended filing corrects exercise-price information and clarifies the vesting schedule.